Qiagen’s Rumored Sale Is a Warning for Germany’s Public Markets

What does it say about a stock market when a globally relevant healthcare company suddenly looks more valuable because a private-equity buyer is interested? That is the uncomfortable question behind the latest Qiagen rumors. The immediate story is a possible EQT takeover. The more important story is whether public markets have been undervaluing a strategic asset—or whether investors are simply pricing in real operational problems.

Reports on October 20 said EQT had submitted a binding offer of more than $50 per share, valuing Qiagen at more than $10 billion. KKR was also reported to have made an offer, while Qiagen’s supervisory board was expected to review the proposals this week. As Reuters reported in July, EQT, Advent and KKR had already shown early interest. None of that guarantees a transaction.

The market’s response was swift: one report put Qiagen’s shares at €43.84 after a 5.7% rise. But the dollar-denominated offer and euro-denominated share price cannot be compared as a simple takeover premium without accounting for the currency. The deal remains a possibility, not an outcome.

Qiagen looks “cheap” because the market has reasons to hesitate

The private-equity narrative is seductive because Qiagen owns a strong position in PCR testing and sample preparation, while about 90% of its revenue comes from consumables. That recurring element can make a diagnostics business attractive to a financial buyer seeking a platform for consolidation. Qiagen is not merely a cyclical laboratory-equipment maker; its consumables base and molecular-diagnostics activities give it strategic weight.

But the public market has not ignored Qiagen without cause. The company cut its 2026 currency-adjusted revenue-growth forecast to 1% to 2%, citing softer US demand and weaker tuberculosis-test demand. Earlier reporting said the forecast had previously called for at least 5% growth. The stock also remains well below its January level of €47.95 in the figures reported in July.

That combination matters. A public investor has to value the company on the earnings it can deliver as an independent business, not on the price a buyer might eventually pay. The next quarterly results are expected on November 10, 2026, and reported analyst expectations put 2026 earnings per share at $2.44. Those are expectations, not results, but they provide a useful test: can Qiagen’s operating performance justify a higher valuation without a takeover?

The bid is a signal of value, not proof of mispricing

EQT’s reported offer may be evidence that Qiagen’s assets have more potential than the current market narrative suggests. It may also reflect what private equity does well: identify businesses that can be reorganized, combined with other assets or financed differently from a listed company.

Our view is that the bid should be treated as a valuation signal, not as a certificate that Qiagen is an obvious bargain. Private-equity buyers do not pay simply because a company is strategically important. They pay when they believe future cash generation, operational improvements or consolidation opportunities can exceed the purchase price and financing costs. That is a forecast about what can be changed, not just a judgment about what Qiagen is today.

The distinction is especially important because takeover rumors can turn a stock into an event-driven wager. Earlier reporting described annualized 30-day volatility of almost 370%, a figure that underlines how sharply expectations can move before a formal agreement exists. A binding offer, even if accurately reported, still has to be accepted, completed and potentially cleared through the relevant process.

Germany’s public market loses if the exit becomes the whole story

The broader concern is not that Qiagen might be bought. Shareholders are entitled to consider a credible offer, and the supervisory board’s responsibility is to assess whether the price reflects the company’s prospects. A competitive process involving EQT and KKR could theoretically improve the outcome for investors.

The concern is what the episode says about Germany’s listed-company ecosystem. Qiagen is presented in the documentation as a major diagnostics business with international revenue, technological assets and a market position that attracts several financial sponsors. Yet the public valuation became more exciting only after the prospect of a private buyer appeared. That is a poor advertisement for the market’s ability to recognize long-term strategic value on its own.

Still, selling is not automatically a loss for the public market. If Qiagen’s growth has genuinely slowed and management cannot persuade investors that digital PCR, laboratory automation and data-driven analysis will improve the trajectory, private ownership may be better positioned to pursue a difficult restructuring. A buyer could unlock value—or simply move a valuable European healthcare asset out of public ownership. The price and the buyer’s plan are therefore inseparable.

The right question is what Qiagen is worth without EQT

For shareholders, the key discipline is to separate two cases. In the takeover case, the relevant issue is whether a credible bidder can offer more and whether the board should accept. In the standalone case, the issue is whether Qiagen can recover growth after its 2026 downgrade and convert its technology and consumables base into stronger earnings.

That is also the answer to the question of whether Qiagen is a good stock to buy: the takeover rumor alone is not enough. It increases the potential upside from a bidding contest, but it also increases the risk that investors are paying for an event that never arrives. We would be particularly skeptical of treating a reported $50-plus offer as a guaranteed floor, since the documentation itself says the transaction remains open and the currencies do not permit a direct premium calculation.

Qiagen may ultimately be worth more inside a buyer’s portfolio than in the public market. If so, the lesson is not simply that EQT spotted a bargain. It is that Germany’s market failed to make the case for one. The responsible verdict is to judge any offer against Qiagen’s independent earnings prospects, not against takeover excitement—and to demand that any sale price compensate shareholders for surrendering a rare listed healthcare champion.